繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 抗肿瘤药 >> 新药推荐 >> OncoGel ™用于食道癌

OncoGel ™用于食道癌

2009-11-07 16:07:53  作者:  来源:互联网  浏览次数:93  文字大小:【】【】【
简介: Product OncoGelPaclitaxel Aqueous Gel InjectionIndicationsOesophageal cancerPhasePhase IIb ongoing for oesophageal cancerDescriptionSustained-release formulation of paclitaxel, a well est ...
 Product 
OncoGel
Paclitaxel Aqueous Gel Injection
Indications
Oesophageal cancer
Phase
Phase IIb ongoing for oesophageal cancer
Description
Sustained-release formulation of paclitaxel, a well established chemotherapy agent, for local injection, which is designed to provide high concentrations of paclitaxel at the tumour site while minimising exposure to other organs.
Further Information
Patients with oesophageal cancers have very few treatment options and life expectancy can be less than two years from first diagnosis. Data indicates that around 15,000 new cases of oesophageal cancer are reported in the US each year, with 13,000 patients dying of the disease annually.*  
OncoGel™; in an investigational new drug that is being studied in combination with commonly used cancer treatments such as surgery, chemotherapy and radiotherapy to determine if the life expectancy of patients with oesophageal cancer can be extended. OncoGel™; also has the potential to be used in other cancers which are accessible by local injection.
OncoGel™; is being injected directly into the tumour for oesophageal tumours.
In non-clinical models OncoGel™; has been shown to continuously release paclitaxel for up to six weeks to provide concentrations of the drug several orders of magnitude higher at the tumour site than in the blood. In a small Phase IIa study of OncoGel™; in patients with late stage inoperable oesophageal cancer, 70% of patients had a reduction in tumour volume when OncoGel™; was used in combination with radiotherapy. In addition, biopsy samples did not contain tumour cells in almost 40% of patients. A Phase IIb study in 124 patients with operable oesophageal cancer is ongoing.

责任编辑:admin


相关文章
M.V.I.-12(Multi-Vitamin Infusion without Vitamin K)
肺癌新药阿法替尼在欧洲获支持审批
TUDORZA/ PRESSAIR(aclidinium溴化物吸入粉)
Fortesta凝胶获(FDA)批准治疗性腺机能减退症
Azixa™(verubulin, MPC-6827)-治疗多形性胶母细胞瘤
阿糖胞苷注射剂(德泊噻DepoCyt)
注射用左乙拉西坦注射剂(开浦兰,Keppra)
AQUALIFT™
生长激素电子智能注射器Easypod
埃美丁™富马酸依美斯汀滴眼液-3分钟起效,有效缓解过敏症状
FDA批准ONGLYZA ™(saxagliptin)用于2型糖尿病治疗
 

最新文章

更多

· Removab(Catumaxomab)...
· 希罗达(卡培他滨片)Xe...
· ZOLINZA(vorinostat,伏...
· 聚乙二醇干扰素(SYLATRO...
· 苹果酸舒尼替尼胶囊|Sut...
· 地尼白介素-2(DENILEUK...
· GARDASIL(基因重组四价...
· Jakafi(Ruxolitinib)片
· INFED(IRON DEXTRAN COM...
· 格拉司琼透皮贴片(gran...

推荐文章

更多

· Removab(Catumaxomab)...
· 希罗达(卡培他滨片)Xe...
· ZOLINZA(vorinostat,伏...
· 聚乙二醇干扰素(SYLATRO...
· 苹果酸舒尼替尼胶囊|Sut...
· 地尼白介素-2(DENILEUK...
· GARDASIL(基因重组四价...
· Jakafi(Ruxolitinib)片
· INFED(IRON DEXTRAN COM...
· 格拉司琼透皮贴片(gran...

热点文章

更多